{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:59:19Z","timestamp":1792519159432,"version":"4.5.0"},"reference-count":195,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003398","name":"Shanxi Scholarship Council of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019447","name":"Applied Basic Research Project of Shanxi Province, China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cholangiocarcinoma is the second most common primary liver cancer, and its global incidence has increased in recent years. Radical surgical resection and systemic chemotherapy have traditionally been the standard treatment options. However, the complexity of cholangiocarcinoma subtypes often presents a challenge for early diagnosis. Additionally, high recurrence rates following radical treatment and resistance to late-stage chemotherapy limit the benefits for patients. Immunotherapy has emerged as an effective strategy for treating various types of cancer, and has shown efficacy when combined with chemotherapy for cholangiocarcinoma. Current immunotherapies targeting cholangiocarcinoma have predominantly focused on T lymphocytes within the tumor microenvironment, and new immunotherapies have yielded unsatisfactory results in clinical trials. Therefore, it is essential to achieve a comprehensive understanding of the unique tumor microenvironment of cholangiocarcinoma and the pivotal role of T lymphocytes within it. In this review, we describe the heterogeneous immune landscape and intercellular communication in cholangiocarcinoma and summarize the specific distribution of T lymphocytes. Finally, we review potential immune checkpoints in cholangiocarcinoma.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1482291","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:19:55Z","timestamp":1736317195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints"],"prefix":"10.3389","volume":"15","author":[{"given":"Yunyan","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinggui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002759","article-title":"Advances in immunotherapy for biliary tract cancers","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin Med J"},{"key":"B2","article-title":"Cholangiocarcinoma: epidemiology and imaging-based review","volume":"107","author":"Kidanemariam","year":"2024","journal-title":"Rhode Island Med J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41420-022-00932-7","article-title":"Suppressive effects of umbilical cord mesenchymal stem cell-derived exosomal miR-15a-5p on the progression of cholangiocarcinoma by inhibiting CHEK1 expression","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","author":"Khan","year":"2019","journal-title":"Liver International: Off J Int Assoc Study Liver"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0000923","DOI":"10.1128\/cmr.00009-23","article-title":"Clonorchiasis and opisthorchiasis: epidemiology, transmission, clinical features, morbidity, diagnosis, treatment, and control","volume":"37","author":"Qian","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101851","DOI":"10.1016\/j.suronc.2022.101851","article-title":"Molecular diagnostics and biomarkers in cholangiocarcinoma","volume":"44","author":"Brown","year":"2022","journal-title":"Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1733528","article-title":"Cholangiocarcinoma: novel therapeutic targets","volume":"24","author":"Sato","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"B13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cncr.v129.2","article-title":"The multidisciplinary management of cholangiocarcinoma","volume":"129","author":"Ohaegbulam","year":"2023","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.04.002","article-title":"Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged","volume":"45","author":"Alabraba","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/14728222.2022.2029412","article-title":"Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications","volume":"26","author":"Kankeu Fonkoua","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"B18","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet (London England)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The role of cancer-associated fibroblasts and fibrosis in liver cancer","volume":"12","author":"Affo","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/imr.v302.1","article-title":"Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment","volume":"302","author":"Desbois","year":"2021","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/ijms19102885","article-title":"The role of stroma in cholangiocarcinoma: the intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium","volume":"19","author":"Gentilini","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s42255-022-00582-0","article-title":"Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix","volume":"4","author":"Kay","year":"2022","journal-title":"Nat Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.72534","article-title":"Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance","volume":"18","author":"Zhang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1331806","DOI":"10.1080\/2162402X.2017.1331806","article-title":"Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma","volume":"6","author":"Atanasov","year":"2017","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1186\/s12885-015-1795-7","article-title":"Prognostic significance of macrophage invasion in hilar cholangiocarcinoma","volume":"15","author":"Atanasov","year":"2015","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs123","article-title":"Tumor-associated neutrophils: friend or foe","volume":"33","author":"Fridlender","year":"2012","journal-title":"Carcinogenesis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.01.010","article-title":"NKp46 receptor-mediated interferon-gamma production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis","volume":"48","author":"Glasner","year":"2018","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"108168","DOI":"10.1016\/j.intimp.2021.108168","article-title":"Adenoma to carcinoma: A portrait of molecular and immunological profiles of colorectal sporadic tumors","volume":"100","author":"Elsayed","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.10.006","article-title":"Once upon a prime: DCs shape cancer immunity","volume":"9","author":"Zagorulya","year":"2023","journal-title":"Trends Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00005-020-00601-6","article-title":"Immune checkpoint blockade in cancer immunotherapy: mechanisms, clinical outcomes, and safety profiles of PD-1\/PD-L1 inhibitors","volume":"68","author":"Yan","year":"2020","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01310-3","article-title":"Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles","volume":"124","author":"Ye","year":"2021","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"13311","DOI":"10.3390\/ijms222413311","article-title":"Immune regulatory processes of the tumor microenvironment under Malignant conditions","volume":"22","author":"Pansy","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.cellimm.2021.104295","article-title":"MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target","volume":"361","author":"Ma","year":"2021","journal-title":"Cell Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32222","article-title":"Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma","volume":"75","author":"Zimmer","year":"2022","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.401","article-title":"Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma","volume":"118","author":"Kitano","year":"2018","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Trans Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The tumor microenvironment in cholangiocarcinoma progression","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: Perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-023-02934-4","article-title":"Transcription factors in fibroblast plasticity and CAF heterogeneity","volume":"42","author":"Melchionna","year":"2023","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/carcin\/bgt397","article-title":"CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils","volume":"35","author":"Zhou","year":"2014","journal-title":"Carcinogenesis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v111.2","article-title":"Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma","volume":"111","author":"Fukuda","year":"2020","journal-title":"Cancer Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","article-title":"Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.10.037","article-title":"Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma","volume":"74","author":"Huang","year":"2021","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004892","article-title":"Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities","volume":"10","author":"Lin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/ijms23042168","article-title":"CXCR2 receptor: regulation of expression, signal transduction, and involvement in cancer","volume":"23","author":"Korbecki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/febs.2018.285.issue-4","article-title":"Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages","volume":"285","author":"Bonelli","year":"2018","journal-title":"FEBS J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.32150","article-title":"The immunogenomic landscape of resected intrahepatic cholangiocarcinoma","volume":"75","author":"Carapeto","year":"2022","journal-title":"Hepatology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J Hepatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1157","article-title":"Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32624","article-title":"Proteogenomic characterization of cholangiocarcinoma","volume":"77","author":"Deng","year":"2023","journal-title":"Hepatology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.045","article-title":"Refining classification of cholangiocarcinoma subtypes via proteogenomic integration reveals new therapeutic prospects","volume":"164","author":"Cho","year":"2023","journal-title":"Gastroenterology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-1101","article-title":"Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis","volume":"10","author":"Bao","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment","volume":"36","author":"Woo","year":"2015","journal-title":"Trends Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.3390\/ijms23084187","article-title":"The tumor microenvironment drives intrahepatic cholangiocarcinoma progression","volume":"23","author":"Mancarella","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/0115680096267791231115101107","article-title":"The tumor immune microenvironment plays a key role in driving the progression of cholangiocarcinoma","volume":"24","author":"Zhang","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.026","article-title":"Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules","volume":"71","author":"Zhou","year":"2019","journal-title":"J Hepatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.610","article-title":"Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer","volume":"109","author":"Goeppert","year":"2013","journal-title":"Br J Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166497","article-title":"Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma","volume":"14","author":"Shang","year":"2023","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"75","author":"Ma","year":"2021","journal-title":"J Hepatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14814","article-title":"Implication of CD69(+) CD103(+) tissue-resident-like CD8(+) T cells as a potential immunotherapeutic target for cholangiocarcinoma","volume":"41","author":"Kim","year":"2021","journal-title":"Liver International: Off J Int Assoc Study Liver"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat Metab"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1602086","article-title":"Cutting edge: chromatin accessibility programs CD8 T cell memory","volume":"198","author":"Scharer","year":"2017","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1038\/s41598-017-02608-0","article-title":"Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma","volume":"7","author":"Ritter","year":"2017","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-019-0554-8","article-title":"HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1","volume":"7","author":"Jing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972021","article-title":"Roles of CD4+ T cells as mediators of antitumor immunity","volume":"13","author":"Kravtsov","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e2200169","DOI":"10.1002\/adbi.202200169","article-title":"CD4(+) cytotoxic T lymphocytes in cancer immunity and immunotherapy","volume":"7","author":"Wang","year":"2023","journal-title":"Advanced Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2022.05.001","article-title":"CD4(+) cytotoxic T cells - phenotype, function and transcriptional networks controlling their differentiation pathways","volume":"247","author":"Preglej","year":"2022","journal-title":"Immunol Lett"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S339607","article-title":"Based on BATMAN-TCM to explore the molecular mechanism of xihuang pill regulating immune function to treat breast precancerous lesions","volume":"13","author":"Li","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0318-097R","article-title":"T lymphocyte subsets in cancer immunity: Friends or foes","volume":"105","author":"Chraa","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-019-01146-9","article-title":"T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer","volume":"42","author":"Chang","year":"2019","journal-title":"Arch Pharmacal Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","article-title":"Regulatory T cells restrain interleukin-2- and blimp-1-dependent acquisition of cytotoxic function by CD4(+) T cells","volume":"52","author":"\u015aledzi\u0144ska","year":"2020","journal-title":"Immunity"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0206","article-title":"CD4 T-cell exhaustion: does it exist and what are its roles in cancer","volume":"27","author":"Miggelbrink","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1233261","article-title":"Cytotoxic CD4 T cells in the mucosa and in cancer","volume":"14","author":"Venkatesh","year":"2023","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1271236","article-title":"Cytotoxic CD4(+) T cells in chronic viral infections and cancer","volume":"14","author":"Malyshkina","year":"2023","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Sci (New York NY)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"106003","DOI":"10.1016\/j.isci.2023.106003","article-title":"Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma","volume":"26","author":"Shen","year":"2023","journal-title":"iScience"},{"key":"B100","article-title":"Predominant expression of Th1-type cytokines in primary hepatic cancer and adjacent liver tissues","volume":"6","author":"Qiu","year":"2007","journal-title":"Hepatobiliary Pancreatic Dis International: HBPD Int"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.5053","article-title":"Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma","volume":"15","author":"Kasper","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.704","article-title":"Spatial distribution and prognostic implications of tumor-infiltrating foxP3- CD4+ T cells in biliary tract cancer","volume":"53","author":"Kim","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B103","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12967-022-03424-5","article-title":"Single-cell landscape of immunocytes in patients with extrahepatic cholangiocarcinoma","volume":"20","author":"Xu","year":"2022","journal-title":"J Transl Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"101954","DOI":"10.1016\/j.tranon.2024.101954","article-title":"Identification of clinically relevant subsets CD39(+)PD-1(+)CD8(+) T cells and CD39(+) regulatory T cells in intrahepatic cholangiocarcinoma using single-cell CyTOF","volume":"44","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25050","article-title":"Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma","volume":"9","author":"Ueno","year":"2018","journal-title":"Oncotarget"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-020-01967-y","article-title":"Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma","volume":"50","author":"Asahi","year":"2020","journal-title":"Surg Today"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp Mol Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"B109","doi-asserted-by":"publisher","first-page":"216043","DOI":"10.1016\/j.canlet.2022.216043","article-title":"CD8(+) T cell exhaustion and cancer immunotherapy","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B110","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/bs.ircmb.2018.07.004","article-title":"T cells and regulated cell death: kill or be killed","volume":"342","author":"Spetz","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8(+) T cell metabolism in infection and cancer","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.73949","article-title":"Tumor microenvironment and its implications for antitumor immunity in cholangiocarcinoma: future perspectives for novel therapies","volume":"18","author":"Cao","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.2010046","article-title":"Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells","volume":"25","author":"Wang","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2022.01.009","article-title":"Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance","volume":"156","author":"Ravichandra","year":"2022","journal-title":"Adv Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2023.01.006","article-title":"Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma","volume":"15","author":"Ying","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12957-020-02082-5","article-title":"PD-1\/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome","volume":"18","author":"Tian","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/OTT.S288982","article-title":"Clinicopathological and prognostic significance of immunoscore and PD-L1 in intrahepatic cholangiocarcinoma","volume":"14","author":"Wu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.7150\/jca.51038","article-title":"High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma","volume":"12","author":"Xu","year":"2021","journal-title":"J Cancer"},{"key":"B120","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12957-023-03009-6","article-title":"Prognostic values of tissue-resident CD8(+)T cells in human hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"21","author":"Chen","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41379-020-00702-9","article-title":"Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes","volume":"34","author":"Yugawa","year":"2021","journal-title":"Modern Pathol: An Off J United States Can Acad Pathol Inc"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1075813","article-title":"The emerging role of regulatory cell-based therapy in autoimmune disease","volume":"13","author":"Ghobadinezhad","year":"2022","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619932","article-title":"Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and in vitro Expanded iTregs","volume":"12","author":"Hui","year":"2021","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-1-0716-2647-4_6","article-title":"Differentiation of peripheral treg","volume":"2559","author":"Almeida-Santos","year":"2023","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1321228","article-title":"Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity","volume":"14","author":"Santosh Nirmala","year":"2023","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41584-023-00906-8","article-title":"T(reg) cell-inducing nanoparticles show promise for treating OA","volume":"19","author":"McHugh","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"102986","DOI":"10.1016\/j.jaut.2022.102986","article-title":"Engineered Treg cells: The heir to the throne of immunotherapy","volume":"144","author":"Stucchi","year":"2024","journal-title":"J Autoimmunity"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1065570","article-title":"Editorial: Regulatory T lymphocytes in cancer immunity","volume":"13","author":"Adeegbe","year":"2022","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"115142","DOI":"10.1016\/j.biopha.2023.115142","article-title":"Why Treg should be the focus of cancer immunotherapy: The latest thought","volume":"168","author":"Liu","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"110091","DOI":"10.1016\/j.intimp.2023.110091","article-title":"MUC1 induces the accumulation of Foxp3(+) Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR\/PI3K\/Akt signaling pathway","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1002\/iid3.v10.11","article-title":"Forkhead box M1 recruits FoxP3(+) Treg cells to induce immune escape in hilar cholangiocarcinoma","volume":"10","author":"Ma","year":"2022","journal-title":"Immunity Inflammation Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.005","article-title":"Characterisation of the immune-related transcriptome in resected biliary tract cancers","volume":"86","author":"Ghidini","year":"2017","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.043","article-title":"Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target","volume":"77","author":"Alvisi","year":"2022","journal-title":"J Hepatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1037945","article-title":"Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B141","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/cells12060851","article-title":"Expression of checkpoint molecules in the tumor microenvironment of intrahepatic cholangiocarcinoma: implications for immune checkpoint blockade therapy","volume":"12","author":"Heij","year":"2023","journal-title":"Cells"},{"key":"B142","doi-asserted-by":"publisher","first-page":"eaay4458","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci Advances"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41467-021-22965-9","article-title":"PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/d41573-022-00003-7","article-title":"Comparing development strategies for PD1\/PDL1-based immunotherapies","volume":"21","author":"Li","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.707967","article-title":"Case report: A case report and literature review on severe bullous skin reaction induced by anti-PD-1 immunotherapy in a cervical cancer patient","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"viii210","DOI":"10.1093\/annonc\/mdy282.009","article-title":"Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study","volume":"29","author":"Ueno","year":"2018","journal-title":"Ann Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.6.823","article-title":"Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses","volume":"194","author":"Sutmuller","year":"2001","journal-title":"J Exp Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705378","article-title":"CTLA-4 synergizes with PD1\/PD-L1 in the inhibitory tumor microenvironment of intrahepatic cholangiocarcinoma","volume":"12","author":"Guo","year":"2021","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0474-1","article-title":"Clinical implications of cytotoxic T lymphocyte antigen-4 expression on tumor cells and tumor-infiltrating lymphocytes in extrahepatic bile duct cancer patients undergoing surgery plus adjuvant chemoradiotherapy","volume":"12","author":"Lim","year":"2017","journal-title":"Target Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30482","article-title":"Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer","volume":"69","author":"Xie","year":"2019","journal-title":"Hepatology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: An update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01132-19","article-title":"Differential expression of immune checkpoint molecules on CD8(+) T cells specific for immunodominant and subdominant herpes simplex virus 1 epitopes","volume":"94","author":"Carroll","year":"2020","journal-title":"J Virol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01838-y","article-title":"Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma","volume":"127","author":"Konishi","year":"2022","journal-title":"Br J Cancer"},{"key":"B159","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B160","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","article-title":"Targeting TIGIT for cancer immunotherapy: recent advances and future directions","volume":"12","author":"Zhang","year":"2024","journal-title":"biomark Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31466","article-title":"Transcriptome profiling identifies TIGIT as a marker of T-cell exhaustion in liver cancer","volume":"73","author":"Ostroumov","year":"2021","journal-title":"Hepatology"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"B169","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","article-title":"Clinical landscape of LAG-3-targeted therapy","volume":"14","author":"Chocarro","year":"2022","journal-title":"Immuno-oncol Technol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.003","article-title":"LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation","volume":"30","author":"Sung","year":"2022","journal-title":"Mol Ther"},{"key":"B171","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-21-0845","article-title":"Open-label, dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers","volume":"28","author":"Diab","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.8.4834","article-title":"STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors","volume":"176","author":"Verdeil","year":"2006","journal-title":"J Immunol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-024-10184-9","article-title":"OX40\/OX40 ligand and its role in precision immune oncology","volume":"43","author":"Thapa","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B174","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12967-022-03670-7","article-title":"Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of Malignancies","volume":"20","author":"Giampietri","year":"2022","journal-title":"J Transl Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12072-021-10177-8","article-title":"The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients","volume":"15","author":"Kida","year":"2021","journal-title":"Hepatol Int"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1653744","article-title":"Concepts for agonistic targeting of CD40 in immuno-oncology","volume":"16","author":"Richards","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B177","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1431598","article-title":"Inhibition of IL-10 and TGF-beta receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells","volume":"14","author":"Thepmalee","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02746-x","article-title":"Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40\/CD40L on dendritic cells","volume":"70","author":"Sadeghlar","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J Hepatol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588682","article-title":"The role of GITR\/GITRL interaction in autoimmune diseases","volume":"11","author":"Tian","year":"2020","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1512588","article-title":"Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy","volume":"22","author":"Riccardi","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3A0919-387RR","article-title":"Biological role of GITR\/GITRL in attributes and immune responses of macrophage","volume":"107","author":"Fu","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103354","article-title":"A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand","volume":"188","author":"Ray","year":"2012","journal-title":"J Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.02.007","article-title":"ICOS-play: dressing T cells for residency","volume":"43","author":"Park","year":"2022","journal-title":"Trends Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202201615","article-title":"ICOS costimulation is indispensable for the differentiation of T follicular regulatory cells","volume":"6","author":"Panneton","year":"2023","journal-title":"Life Sci Alliance"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16151","article-title":"Therapy for advanced cholangiocarcinoma: Current knowledge and future potential","volume":"25","author":"Wang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.336","article-title":"Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC)","volume":"37","author":"Floudas","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/vaccines9050422","article-title":"The emerging role of immunotherapy in intrahepatic cholangiocarcinoma","volume":"9","author":"Fiste","year":"2021","journal-title":"Vaccines"},{"key":"B192","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-017-0218-5","article-title":"Combination immunotherapy: a road map","volume":"5","author":"Ott","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B193","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","article-title":"Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition","volume":"157","author":"Yuan","year":"2021","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab073","article-title":"A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma","volume":"27","author":"Monge","year":"2022","journal-title":"Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1482291\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:20:05Z","timestamp":1736317205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1482291\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":195,"alternative-id":["10.3389\/fimmu.2024.1482291"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1482291","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1482291"}}